Stockreport

4DMT Provides Company Update and Anticipated Development Milestones for 2026

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomi [Read more]